Dr. Stephen M. Ansell, MD

Dr. Ansell practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Ansell's NPI, 1558335935, was assigned on February 14, 2006. Dr. Ansell graduated from University of Pretoria Faculty of Medicine in 1986. Dr. Ansell holds Minnesota license 38954.

Dr. Ansell's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Ansell's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Ansell is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Ansell to 1 more clinical lab and 1 hospice, each named with a free account. Dr. Ansell's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ansell practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Ansell's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Ansell is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Ansell's licenses on file in 2 states: Minnesota and Arizona.

Dmand AI lists chronic anemia, chronic leukemia and lymphoma among the conditions Dr. Ansell treats.

CMS data shows 2,469 Medicare services from Dr. Ansell across 6 procedure codes in 2024, for 134 Medicare patients. Medicare paid $31,069 for them.

CMS counts 134 Medicare patients who saw Dr. Ansell in 2024. The largest group is 65 to 74, with 71 patients. 63% of them have high blood pressure, and 60% have high cholesterol. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ansell's median patient age at 71, with 50% women.

In 2024, Dr. Ansell wrote 86 Medicare Part D claims for 26 patients. 83% of them were for generic drugs. CMS names the drug for 30 of them, across 2 drugs with 11 or more claims each, at $282,519 in total drug cost. In 2023, CMS named 93 claims across 5 drugs.

Dr. Ansell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ansell as offering telehealth.

Dmand AI links 473 papers to Dr. Ansell, published from 2004 to 2025. 2022 was the busiest year, with 30. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin. Dr. Ansell has published most often in Blood. Dr. Ansell's most frequent co-authors are Thomas E. Witzig, MD, Thomas M. Habermann, MD and David J. Inwards, MD.

Dmand AI links Dr. Ansell to 23 clinical trials, 9 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Lymphoma, Non-Hodgkin and Hodgkin Disease. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Ansell that name 2 trials.

CMS Open Payments shows 23 general payments to Dr. Ansell from 7 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 69% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $10,114. It also lists 23 research payments totaling $289,909 from 2017 to 2025, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Ansell, most recently Regional Top Doctor in 2014.

Dr. Ansell graduated from University of Pretoria Faculty of Medicine in 1986. Dr. Ansell is a member of ASCO.

Dr. Ansell is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.